Skip to main content
OpenTrials

Clinical trial condition

HNSCC

Explore clinical trials studying HNSCC. Study availability and eligibility vary by location and protocol.

72 public trials 36 recruiting studies
Refine in advanced search Browse all conditions

HNSCC trial results

Completed

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

NCT04997902

Conditions
Carcinoma, Carcinoma, Squamous Cell, Congenital Abnormalities, +21 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Lake Nona DDU (Florida Cancer Specialists) Orlando, Florida, United States
  • University of Maryland School of Medicine (Marlene and Stewart Greenebaum Comprehensive Cancer Center) Baltimore, Maryland, United States
  • Johns Hopkins University School of Medicine (Sidney Kimmel Comprehensive Cancer Center) Baltimore, Maryland, United States
View Trial Details
Completed

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

NCT04354246

Conditions
Adnexal Diseases, Advanced Cancer, Blood Protein Disorders, +53 more
Locations
  • Florida Cancer Specialists Sarasota, Florida, United States
  • Massachusetts General Hospital. Boston, Massachusetts, United States
  • START Midwest. Grand Rapids, Michigan, United States
  • The Ohio State University Comprehensive Cancer Center. Columbus, Ohio, United States
View Trial Details
Completed

Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT03480672

Conditions
Carcinoma, Carcinoma, Squamous Cell, HNSCC, +6 more
Locations
  • Charité - Universitätsmedizin Berlin; Klinik für Radioonkologie und Strahlentherapie CVK Berlin, Germany
  • Charité - Universitätsmedizin, CVK und CCM, Klinik für Hals-Nasen-Ohrenheilkunde Berlin, Germany
  • Klinikum Bielefeld, Onkologie/Hämatologie/ Palliativmedizin Bielefeld, Germany
  • Universitätsklinikum Bonn; Med. Klinik III / ZIM, Hämatologie/Onkologie Bonn, Germany
View all 16 locations
View Trial Details
Completed

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

NCT03082534

Conditions
Carcinoma, Carcinoma, Squamous Cell, Cutaneous Squamous Cell Carcinoma, +37 more
Locations
  • UCSD Moores Cancer Center La Jolla, California, United States
  • University of California Los Angeles Cancer Center Los Angeles, California, United States
  • University of Michigan Cancer Center Ann Arbor, Michigan, United States
  • Washington School of Medicine Cancer Center St Louis, Missouri, United States
View Trial Details
Completed

Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

NCT04811027

Conditions
Carcinoma, Carcinoma, Squamous Cell, HNSCC, +6 more
Locations
  • University of Alabama at Birmingham (UAB) - O'Neal Cancer Center Birmingham, Alabama, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • Oncology Consultants Houston, Texas, United States
  • Macquarie University Hospital Macquarie Park, New South Wales, Australia
View all 28 locations
View Trial Details

Related conditions